Difference Expressions CD34 in Acute Myeloid Leukemia Cell Culture in the Administration of Cytarabine-Daunorubicine Dose Standards

Muhammad Saiful Rahman, Paulus Budiono Notopuro, Suprapto Ma'at, Made Putra Sedana, Arifoel Hajat


The cure rate for patients with Acute Myeloid Leukemia (AML) is 20-75%. Standard-dose cytarabine + (SDAC)-daunorubicine gives a remission rate of ± 60%, and the case of relapse is frequently found. In-vivo CD34 expression is a reliable and straightforward test that must evaluate AML patients' response to predict the response of chemotherapy + induction phase accurately. Differences in in-vitro CD34 expression are expected to be able to predict chemosensitivity in AML patients. An experimental post-test-only control group study was conducted from May to December 2019, and 8 AML subjects were found. Peripheral Blood Mononuclear Cells (PBMC) were isolated from peripheral blood samples of patients with AML collected in EDTA tubes. The PBMC isolated from peripheral blood were divided into two groups, and each group contained 106 PBMC cells in culture media. The control group (without treatment) and the SDAC-daunorubicine group were 0 + incubated for 4 hours at 37 C with a 5% CO2 atmosphere. The expression of CD34 was measured using FACSCalibur™, while + CD34+ percentage was calculated with CellQuest™ software. The percentage of CD34 in the control, SDAC + DNR, showed a significant difference with p < 0.001. This study showed a significant difference between the control group and the group + administered with the standard dose of cytarabine-daunorubicine with p < 0.001. The average CD34 expression in the + SDAC-DNR treatment group was higher than in the control group. CD34 markers cannot be used as predictors of chemosensitivity in the administration of chemotherapy.


Acute myeloid leukemia, CD34, cytarabine-daunorubicine, flow cytometry

Full Text:



Döhner H, Estey EH, Amadori S, Appelbaum FR,

Büchner T, et al. Diagnosis and management of acute

myeloid leukemia in adults: Recommendations from

an international expert panel, on behalf of the

European Leukemia Net. Blood, 2010; 115(3): 453-474.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA,

Jemal A. Global cancer statistics 2018: GLOBOCAN

estimates of incidence and mortality worldwide for 36

cancers in 185 countries. CA. Cancer J. Clin, 2018; 68(6):


Novilla A. Thesis aktivitas dan mekanisme molekuler

antikanker in-vitro senyawa turunan kalkon terhadap

sel lini mieloid HL60 dan K562. Biosience Research,

; 2011: 731-740.

Murphy T, Yee KWL. Cytarabine and daunorubicin for

the treatment of acute myeloid leukemia. Expert Opin.

Pharmacother, 2017; 18(16): 1765-1780.

Wu D, Duan C, Chen L, Chen S. Efficacy and safety of

different doses of cytarabine in consolidation therapy

for adult acute myeloid leukemia patients: A network

meta-analysis. Sci. Rep, 2017; 7(1): 1-10.

Ma'at S. Kultur sel. Teknik dasar kultur sel. 1 Ed.,

Surabaya, Airlangga University Press, 2011; 3-25.

Heasman SA, Zaitseva L, Bowles KM, Rushworth SA,

MacEwan DJ. Protection of acute myeloid leukemia

cells from apoptosis induced by front-line

chemotherapeutics is mediated by haem oxygenase-1.

Oncotarget, 2011; 2(9): 658-668.

Ersvaer E, Brenner AK, Vetås K, Reikvam H, Bruserud Ø.Effects of cytarabine on activation of human

T-cells-cytarabine has concentration-dependent

effects that are modulated both by valproic acid and

all-trans retinoic acid. BMC Pharmacol Toxicol, 2015;

(1): 1-16.

Maskito VJ, Notopuro PB, Ma'at S, Sedana MP. Karya

akhir perbandingan indeks proliferasi kultur sel

lekemia mieloid akut setelah pemberian dosis standar

sitarabin-daunorubisin, sitarabin dosis tinggi dan

azacitidine. Surabaya, 2019; 49-50.

O'Donnell MR, Tallman MS, Abboud CN, Altman JK,

Appelbaum FR, et al. Acute myeloid leukemia, version

2017, NCCN clinical practice guidelines in oncology.

J. Natl. Compr. Cancer Netw, 2017; 15(7): 926-957.

Rahmadin B, Wahid I, Yaswir R. Artikel penelitian profil

penderita leukemia mieloblastik akut di bagian

penyakit. J. Kesehat. Andalas, 2017; 6(3): 495-501.

WHO. Acute myelogenous leukemia (including acute

promyelocytic leukemia). 2014 Rev. Cancer Med. (list

of essential medicines), 2014; 1-14.

Blair HA. Daunorubicin/cytarabine liposome: A review

in acute myeloid leukemia. Drugs, 2018; 78(18):


Costello RT, Mallet F, Gaugler B, Sainty D, Arnoulet C,

- et al. Human acute myeloid leukemia /Cd38

progenitor cells have decreased sensitivity to

chemotherapy and Fas-induced apoptosis, reduced

immunogenicity, and impaired dendritic cell

transformation capacities. Cancer Res, 2000; 60(16):


Aramvash A, Chadegani AR, Lotfi S. Evaluation of

apoptosis in multipotent hematopoietic cells of bone

marrow by anthracycline antibiotics. Iran. J. Pharm.Res, 2017; 16(3): 1206-1215.

DOI: http://dx.doi.org/10.24293/ijcpml.v27i2.1623


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.